El fondo de inversión Columbus Venture Patners y Asklepios invertirán hasta €9M en el sector ‘bio’ guipuzcoano

, , , , ,
Integral service around a transaction
BY : Diego Gutiérrez18/09/2017
El fondo de capital riesgo Columbus y la compañía estadounidense Asklepios constituyen la joint venture Viralgen para invertir en la apertura de una planta de vectores virales en San Sebastián.

Columbus Venture Partners es un fondo capital de riesgo valenciano especializado en inversiones de alto crecimiento en la industria biológica española. El fondo llevaba varios años en relación con Asklepios, especializada en terapias génicas, para determinar la manera de realizar proyectos en común.

En este nuevo proyecto Columbus aporta la inversión, entre €7M y €9M, y Asklepios el know how, formando una sociedad conjunta a partes iguales. De esta forma ha surgido la joint venture Viralgen, con el objetivo de invertir en una nueva planta de producción de vectores virales adenoasociados en el parque de Mlramón, en San Sebastián. Estos vectores, utilizados en enfermedades raras de origen genético, transportan el gen correcto que se integra en la célula enferma corrigiendo su defecto de funcionamiento.

La inversión de esta nueva joint venture puede llevar al parque guipuzcoano de Miramón a convertirse en un polo biotecnológico de primer orden. El objetivo de la nueva planta es reducir la necesidad de las biotecnológicas europeas de contar con estos vectores virales, cuya producción conlleva un proceso de muy complejo y lento. De hecho, existe una lista de espera de hasta dos años para algunos productos que se requieren en ensayos clínicos. La planta contará, cuando esté a pleno rendimiento, con tres líneas de producción, además de laboratorios, y empleará entre 40 y 50 personas.

Columbus ha anunciado su intención de mantenerse un plazo no superior a diez años, con una rentabilidad de tres veces para sus inversores. El fondo, impulsado por Javier García y Damiá Tormo (creadores de Bioncotech y Artax), tiene en cartera, entre otras, a empresas como Aura Bioscience, Polypeptide Therapeutic y VivetTherapeutics.

Rondas de financiación del sector biotecnológico en España 2016-17

El fondo de inversión Columbus Venture Patners y Asklepios invertirán hasta €9M en el sector ‘bio’ guipuzcoano

 
Otros post que te pueden interesar

La biotecnología española consigue el apoyo de los inversores: 4 empresas han hecho rondas superiores a los €3M en Mayo

Si estás buscando inversores, quieres comprar o vender una empresa, ponte en contacto con nosotros. Abra-Invest cuenta con un equipo experto en cada área a tu disposicón. Llama al +34 946424142 o rellena el formulario de contacto.

The M&A Professionals

Meet our services

MEET
OUR
metodologY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
"Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu